Colorectal cancer health services research study protocol: the CCR-CARESS observational prospective cohort project by Quintana López, Jose Maria et al.
Quintana et al. BMC Cancer  (2016) 16:435 
DOI 10.1186/s12885-016-2475-ySTUDY PROTOCOL Open AccessColorectal cancer health services research
study protocol: the CCR-CARESS
observational prospective cohort project
José M. Quintana1,8* , Nerea Gonzalez1,8, Ane Anton-Ladislao1,8, Maximino Redondo2,8, Marisa Bare3,8,
Nerea Fernandez de Larrea4,8, Eduardo Briones5, Antonio Escobar6,8, Cristina Sarasqueta7,8,
Susana Garcia-Gutierrez1,8, Urko Aguirre1,8 and for the REDISSEC-CARESS/CCR groupAbstract
Background: Colorectal cancers are one of the most common forms of malignancy worldwide. But two significant
areas of research less studied deserve attention: health services use and development of patient stratification risk
tools for these patients.
Methods: Design: a prospective multicenter cohort study with a follow up period of up to 5 years after surgical
intervention. Participant centers: 22 hospitals representing six autonomous communities of Spain. Participants/Study
population: Patients diagnosed with colorectal cancer that have undergone surgical intervention and have consented
to participate in the study between June 2010 and December 2012. Variables collected include pre-intervention
background, sociodemographic parameters, hospital admission records, biological and clinical parameters, treatment
information, and outcomes up to 5 years after surgical intervention. Patients completed the following questionnaires
prior to surgery and in the follow up period: EuroQol-5D, EORTC QLQ-C30 (The European Organization for Research
and Treatment of Cancer quality of life questionnaire) and QLQ-CR29 (module for colorectal cancer), the Duke
Functional Social Support Questionnaire, the Hospital Anxiety and Depression Scale, and the Barthel Index.
The main endpoints of the study are mortality, tumor recurrence, major complications, readmissions, and
changes in health-related quality of life at 30 days and at 1, 2, 3 and 5 years after surgical intervention.
Statistical analysis: In relation to the different endpoints, predictive models will be used by means of multivariate
logistic models, Cox or linear mixed-effects regression models. Simulation models for the prediction of discrete events
in the long term will also be used, and an economic evaluation of different treatment strategies will be performed
through the use of generalized linear models.
Discussion: The identification of potential risk factors for adverse events may help clinicians in the clinical decision
making process. Also, the follow up by 5 years of this large cohort of patients may provide useful information to
answer different health services research questions.
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Colorectal cancers are currently among the most com-
mon cancers in both women and men [1, 2]. Although
many scientific approaches have been applied in this
field, primarily with respect to diagnosis and treatment,
two significant aspects require increased focus, the first
of which is the development of clinical prediction rules
to predict adverse events after surgical treatment of
colorectal cancer patients. While some measurements of
short-term outcomes have been developed, such as the
different versions of the Physiological and Operative Se-
verity Score for the enUmeration of Mortality and mor-
bidity (POSSUM) scoring [3–5], most are not properly
validated in other settings. Furthermore, prediction
models for medium-term follow up (e.g., 1 or 2 years), a
period in which the majority of adverse outcomes after
treatments are observed, are inadequate. Not only robust
clinical outcomes such as mortality, major complica-
tions, relapses or reinterventions should be studied and
related factors identified, but also the determinants of
changes in health-related quality of life, as perceived by
the patient; these are referred to as patient reported out-
come measurements (PROMs) [6–8]. The second signifi-
cant area of research interest is related to health services
research, where multiple factors remain unquantified.
Among these are the quality of the health care process
from the time that initial symptoms present in the pa-
tient to the time at which the patient receives treatment,
equity in access to diagnosis and treatment procedures,
provision of auxiliary support services (including key
psychosocial services) or the cost and effectiveness of
different surgical approaches [9–11].
Study protocol manuscripts are quite common in the
cancer research field but mainly to present clinical trials
of treatments for these patients. Less common, though
no rare, other large and ambitious studies dealing with
quality of care o even health services research have also
published their study protocol. [12, 13].
Study goals and objectives
The purpose of this study is to clarify some of the previ-
ously stated questions and unknown factors. The specific
study objectives are displayed in Fig. 1 and are: 1. To de-
termine risk factors for death or major complications,
reoperations, or readmissions in the short-term; 2. To
determine risk factors for death, tumor recurrence,
major complications, readmission or deterioration in
quality of life in the mid-term; 3. to evaluate patient re-
ported outcomes from before intervention to the end of
the follow-up period. 4. To evaluate the role of bio-
logical markers in the prediction of adverse results; and
5. from a health services research perspective, to evalu-
ate equity, appropriateness, access to care, treatment
cost, and psychosocial support for patients.With the purpose of reducing publication bias and im-
proving reproducibility and to serve as reference for fu-
ture manuscripts derived from this study and for readers
we present the study protocol of this multicenter re-
search work.
Methods/design
Study design
An observational analytic prospective cohort study with
a planned patient follow up period of 5 years following
surgical intervention.
Setting: patients recruited from 22 hospitals represent-
ing 9 provinces in Spain, all of which operate under the
Spanish National Health Service (SNHS), which is re-
sponsible for the majority of the national population. All
applicable residents have free access to their primary
care physician and to the hospital ED. Participating hos-
pitals are: Hospital de Antequera, Hospital Costa del Sol,
Hospital Universitario de Valme, Hospital Universitario
Virgen del Rocío, Hospital Universitario Virgen de las
Nieves, Hospital Universitario de Canarias, Corporació
Sanitaria Parc Taulí, Althaia, Hospital del Mar, Hospital
Clínico San Carlos, Hospital Universitario La Paz, Hos-
pital Infanta Sof ía, Hospital Universitario Fundación
Alcorcón, Hospital Galdakao-Usansolo, Hospital Univer-
sitario Araba, Hospital Universitario Basurto, Hospital
Universitario Cruces, Hospital Hospitalario Donostia,
Hospital Bidasoa, Hospital de Mendaro, Hospital de
Zumarraga and Hospital Universitario Doctor Peset.
Research population: Patients diagnosed with colorec-
tal cancer that underwent surgical intervention at one of
the listed hospitals between June 2010 and December
2012. Patients were informed of the study objectives and
invited to voluntarily participate. Patients were included
in the study sequentially.
Expected duration of the study: patients will be
followed until 5 years after the surgical index interven-
tion, or until death.
Selection criteria
Patients will be deemed eligible for the study if they have
undergone surgery for colorectal cancer in one of the
participating hospitals. Colorectal cancer diagnosis is
based on anatomopathological diagnosis after a biopsy
by colonoscopy [10, 14, 15].
Inclusion criteria: diagnosis with colon cancer (up to
15 cm above the anal margin) and rectum (between the
anal margin and 15 cm above it), where curative or pal-
liative surgery by first time was applied. Exclusion cri-
teria are colon or rectum in situ cancer, inoperable
tumor, severe mental or physical condition which pre-
vents the patient from responding to questionnaires, ter-
minal illness, inability to respond to questionnaires for
any reason, or lack of consent to participate in the study.
Fig. 1 Study objectives
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process. Recruitment data from participating hospitals as
of December 2012 are provided in Table 1.
Methodology
Eligible patients were primarily identified from the surgi-
cal waiting lists of participating hospitals. For those receiv-
ing urgent surgery, identification took place during the
hospitalization period. Depending on the hospital, one of
two strategies were implemented for the inclusion of
patients: a) surgeons or other healthcare professionals ex-
plained the study objectives and invited patients to volun-
tarily participate, during a clinical visit prior to surgery or
during hospitalization for surgery; or b) written informa-
tion about the goals of the study and the consent form for
participation were sent to patients prior to hospitalization
for surgery.
Following the patient selection process, clinical data
and PROMs were collected at specific time points.
Figure 3 summarizes the data-gathering process.
Data collection
A. Medical records and direct data collection
Clinical data were gathered from medical records and
databases by qualified reviewers. A data collection form
and instruction manual were developed to guide the data
collection process to ensure consistency among centers
and reviewers.
Upon hospital admission, baseline data were collected
that included information on patient sociodemographics,
clinical data (including data from the initial diagnosis,
the pre-intervention process, onset of symptoms, habits
and lifestyles (physical activities, alcohol intake or smok-
ing habit), personal and family background, general co-
morbidity data as recorded in the Charlson ComorbidityIndex [16], bowel-specific comorbidities, diagnostic and
screening tests, pre-intervention treatments, and dur-
ation between relevant time points in the diagnostic
process), preoperative data [including analytical, tumor
markers, diagnostic tests and pre-intervention clinical
staging (pre-TNM), and tumor site], data from the out-
patient anesthesia visit prior to surgical intervention
(ASA stage [17], physiological and cardio-respiratory pa-
rameters and tests, and consciousness level based on the
Glasgow scale [18]). Variables from the different versions
of the POSSUM were specifically included to test all
those rules.
Data related to hospital admission
a. Data on the surgical intervention (including type of
intervention, surgical severity, aggravate diagnosis,
type of anesthesia, antibiotic prophylaxis, surgical
approach, type of surgery, invasion of adjacent
organs, additional surgical procedures associated to
local extension of the disease, intra surgical
complications, complication grade, duration of
surgery, and other information specific to the colon-
or recto-surgical intervention), and Intensive Care
Unit (ICU) period information (duration, mechanical
ventilation requirements, parenteral nutrition, anti-
biotics, presence of complications, and death).
b. Anatomical pathology data, including tumor-free
margin, histologic diagnosis, pre-TNM (pTNM),
lymph nodes analyzed and affected, degree of tumor
differentiation, invasion, remission, and biological
markers.
In relation to the biological marker objective of the
study, 800 paraffin-embedded samples were collected for
immunohistochemical analysis to identify clinical and
Fig. 2 Flow chart of the recruitment process
Table 1 Recruited patients by area and hospital
Autonomous
community
Hospital Valid patients
n
Andalucía Antequera 41
Costa del Sol 95
n = 490 Valme 137
Virgen de las Nieves 31
Virgen del Rocío 186
Canarias n = 101 Complejo Hospitalario de Canarias 101
Cataluña Corporació Parc Taulí 332
n = 689 Althaia 100
Hospital del Mar 257
Madrid La Paz 169
Infanta Sofía 64n = 343
Clínico de San Carlos 39
Alcorcón 71
País Vasco Txagorritxu 88
Bidasoa 33
Donostia 245
Mendaro 28
n = 998 Zumarraga 39
Basurto 229
Cruces 139
Galdakao-Usansolo 197
Valencia n = 128 Doctor Pesset 128
Total 2749
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tion, apoptosis and angiogenesis, and the role of these
changes in the occurrence of adverse results such as
cancer relapse and mortality. Samples were collected
from patients attending the following hospitals: Hospital
de Antequera, Hospital Costa del Sol, Hospital de Valme,
Hospital Virgen del Rocío, Hospital Virgen de las
Nieves, Hospital Galdakao-Usansolo, and Hospital
Basurto.
c. Other data related to hospital admission (length of
stay, presence and degree of complications,
treatment information, need for reintervention, or
death). Complications were grouped in the following
categories: surgical, medical, infectious, and
hematological (hemorrhage/thrombosis/embolism)
(see Additional file 1: Table S1).
Data were subsequently collected up to 30 days after
surgery (analytics, diagnostic tests, presence of complica-
tions, readmissions, reintervention, social service re-
quirements, or death). Oncologic treatment information
is shown in the adittional files section as Table 2.
Information was next collected through the first year
of follow-up, including need for and type of treatment
(separately evaluated for colon or rectal tumors), radi-
ation therapy, chemotherapy (treatment schedule, neo or
adjuvant therapy, number of cycles, presence and degree
of treatment complications, and supportive care require-
ments), other medical treatments and psychological sup-
port. Information was also collected on laboratory and
Fig. 3 Data gathering process from baseline to 5 years of follow up. * Patient reported outcomes measures (PROMs) used: EuroQol-5D (EQ-5D),
EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30); QLQ-CR29 (European Organization
for Research and Treatment of Cancer Questionnaire Module for Colorectal Cancer), the Duke-UNC Functional Social Support Questionnaire (FSSQ), the
Hospital Anxiety and Depression Scale (HADS), and the activities of daily living (ADL) Barthel Index (BI). Patient reported outcome at 30 days
were collected in a sub-sample of the overall cohort and after 2 years in a selection of the original hospitals. ICU: Intensive Care Unit
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additional surgeries, tumor recurrence, readmission or
reintervention, and death.
Information collected at the 2-, 3- and 5-year visits
was similar to that of the 1-year visit.
B. Patient reported outcomes measures (PROMs)
Patients completed the following questionnaires prior
to surgery and in the follow up after surgery: EuroQol-
5D (EQ-5D), EORTC QLQ-C30 (The European
Organization for Research and Treatment of Cancer
Quality of Life Questionnaire-C30) and QLQ-CR29
(European Organization for Research and Treatment of
Cancer Questionnaire Module for Colorectal Cancer),
the Duke-UNC Functional Social Support Questionnaire
(FSSQ), the Hospital Anxiety and Depression Scale
(HADS), and the activities of daily living (ADL) Barthel
Index (BI).The EQ-5D is a generic health-related quality of life
(HRQoL) questionnaire which consists of two parts, the
first of which is a description of the state of health in
five dimensions: mobility, self-care, usual activities, pain/
discomfort and anxiety/depression. Each of these dimen-
sions is measured by three answer options that define
different levels of severity. The second part is a visual
analogue scale in which patients rate their health on a
scale displayed in the form of a thermometer (20 mm),
whose ends are 0 (worst imaginable health state) to 100
(best state imaginable health) [19]. This questionnaire
has been translated into and validated in Spanish [20].
The EORTC QLQ-C30 is a HRQoL questionnaire for
evaluating the for cancer patients undergoing treatment,
and has shown good validity and reliability in its Spanish
adaptation (Cronbach’s alpha coefficient of 0.7). It consists
of 30 items, 28 of which have four possible answers (not
at all, a little, quite a bit, very much) and two items with
seven response options (a visual analogue scale where one
Table 2 Basic description of the whole sample at baseline
N (%) Main cancer location
Rectal Colon
Total 2749 770 (28.01) 1979 (71.99)
Gender (Men) 1749 (63.62) 522 (67.79) 1227 (62.00)
Agea 68.50 (10.97) 67.14 (11.26) 69.02 (10.81)
Charlson Comorbidity indexa 2.88 (1.29) 2.83 (1.22) 2.90 (1.32)
ASA index
I,II 1548 (57.92) 450 (59.92) 1098 (57.13)
III 1020 (38.16) 277 (36.88) 743 (38.66)
IV 105 (3.93) 24 (3.20) 81 (4.21)
Surgical approach (main)
Open surgery 1139 (41.89) 307 (40.55) 832 (42.41)
Laparoscopy 1580 (58.11) 450 (59.45) 1130 (57.59)
Laterality of the tumor (Right –transverse side) 834 (42.14) NA 834 (42.14)
pTNM
0, I, II 1581 (57.85) 485 (63.32) 1096 (55.72)
III 892 (32.64) 221 (28.85) 671 (34.11)
IV 260 (9.51) 60 (7.83) 200 (10.17)
Laterality of the tumor: Right-transverse side (appendix, cecum, ascending colon, right hepatic flexure and transverse) versus left side (left splenic flexure,
descending colon, and sigmoid colon)
ASA, American Society of Anesthesiologists
pTNM pathological tumor-node-metastasis staging
aMeans and, in brackets, standard deviation
Quintana et al. BMC Cancer  (2016) 16:435 Page 6 of 12is “very poor” and seven “excellent”) [21, 22]. The time-
frame assessed refers to the previous week. The scores on
each scale are transformed so that the final values are be-
tween 0 and 100. In addition to this overall score, the in-
strument consists of three scales: Global health status, in
which a high score represents a high performance in
terms of overall health; Functional–scale, which consists
of five subscales of operation: physical, role, emotional,
cognitive and social; and a Symptoms scale, describing a
number of symptoms: fatigue, nausea, vomiting, pain, dys-
pnea, insomnia, decreased appetite, constipation, diarrhea
and financial difficulties. A high score on each of these
scales represents a high level of symptoms or problems in
the patient. The QLQ-CR29 questionnaire was developed
following revision of the QLQ-CR38, and has been dem-
onstrated internationally to have both sufficient validity
and reliability to support its use as a supplement to the
EORTC QLQ-C30 for assessing patient-reported out-
comes during treatment for colorectal cancer in clinical
trials and other settings. The QLQ-CR29 questionnaire
contains 29 items, 18 of which address gastrointestinal
symptoms, pain and problems with micturition, and sep-
arate scales are available for participants with or without a
stoma, while separate items address sexual function in
men or women. The response categories for each item are
the same as those used in the QLQ-C30. This question-
naire has also been validated in Spain [23, 24].The HADS questionnaire is designed specifically for
individuals with a physical illness. It is divided into two
subscales, with seven questions pertaining to symptoms
associated with anxiety and seven with depression. Each
of the 14 items consists of a 4-point Likert scale (ranging
from 0 to 3) that applies to the previous week. A total
score for each subscale is then calculated, ranging from
0 to 21 [25]. The HADS has been translated into and
validated in Spanish [26].
The Duke-UNC FSSQ questionnaire is composed of 11
items, each of which is rated on a five-point Likert scale
ranging from 1 to 5: the higher the score, the better the
perceived social support. It assesses subjective social sup-
port in two domains, Confidant support: 6 items (score
range 6–30) and Affective support: 5 items (score range
5–25), and provides an overall social support measure
(score range: 11–55) [27]. The questionnaire has been
translated into and validated in Spanish [28].
The BI questionnaire consists of 10 items that as-
sess the ability to perform certain basic activities of
daily life without help. It includes 2- and 4-point re-
sponse options that produce a score ranging from 0
(completely dependent) to 100 (completely independ-
ent), with intervals of 5 points [29]. The BI has been
translated into and validated in Spanish [30].
Patients were first contacted upon inclusion in the sur-
gical waiting list for a surgical intervention or were
Quintana et al. BMC Cancer  (2016) 16:435 Page 7 of 12interviewed during their hospital admission period.
Questionnaires were subsequently provided at 30 days,
and at 1, 2, 3 and 5 years after surgery. In all instances, a
reminder letter was sent to patients who had not replied
after 15 days. Those who had not responded after a fur-
ther 15 days received another reminder letter and, where
feasible, contacted by telephone.
Questionnaires for the 30 day follow up visit were sent to
patients attending the following hospitals: Hospital Costa
del Sol, Hospital Valme, Hospital Virgen del Rocío, Hospital
Virgen de las Nieves, Corporació Sanitaria Parc Taulí,
Hospital Universitario La Paz, Hospital Infanta Sofía,
Hospital Clínico San Carlos, Hospital Fundación Alcorcón,
Hospital Basurto, Hospital Cruces, Hospital Donostia,
Hospital Galdakao-Usansolo, Hospital Txagorritxu.
Figure 3 illustrates the data gathering process estab-
lished for the entire follow-up period.
Safety considerations
There is no explicit intervention in this study. Neverthe-
less, due to the sensitive nature of the disease and for rea-
sons of confidentiality, all information provided to
patients, either directly by the researchers or reviewers or
included in the questionnaires, avoid references to cancer
or tumors, referring instead, to “your bowel problem”. Pa-
tients may refuse to participate at any time during the
study, whether during recruitment or follow-up. Further-
more, patients who prefer to complete the questionnaire
by phone are permitted to do so. All participating centers
have referring staff available for questions that the patient
or patient’s family may have about the research project.
Follow-up
Follow-up visits up to two years will be performed at all
22 participating hospitals. Due to financial restrictions and
organizational resources, 3- and 5-year follow-up visits
will be restricted to 18 hospitals (Hospital de Antequera,
Hospital Costa del Sol, Hospital Universitario de Valme,
Hospital Universitario Virgen del Rocío, Hospital
Universitario Virgen de las Nieves, Hospital Universitario
de Canarias, Corporació Sanitaria Parc Taulí, Hospital del
Mar, Hospital Clínico San Carlos, Hospital Universitario
La Paz, Hospital Infanta Sofía, Hospital Universitario
Fundación Alcorcón, Hospital Galdakao-Usansolo,
Hospital Universitario Araba, Hospital Universitario
Basurto, Hospital Universitario Cruces, Hospital
Hospitalario Donostia, and Hospital Universitario
Doctor Peset).
Data management and statistical analysis
A. Sample size selection
Studies of predictive model development indicate that
is necessary to include at least 10 events of thedependent variable of interest (in this case: mortality,
major complications, relapses or readmissions) for each
independent variable included in the multivariate logistic
regression model [31, 32]. Therefore, we estimated that
at least 100 events of the dependent variable in the sam-
ple are required in order to ensure that the regression
model would adequately converge. Previous data indi-
cate that the number of events of the dependent variable
mortality would be > 15 % of patients operated on in the
first year, higher that the expected percentages of other
parameters. We therefore estimated that more than 300
events of any of the dependent variables of interest
should be included.
Sampling: we consecutively collected all new cases
until the sample size was achieved.
B. Missing data assumptions and recoding of variables
Tumor location
Tumor location was categorized as follows: the appen-
dix, caecum, ascending colon, hepatic flexure and trans-
verse colon were defined as the right colon, whereas the
splenic flexure, descending colon, sigmoid and rectosig-
moid were defined as the left colon. Rectal tumors were
also recorded.
Symptomatology
Patient pre-intervention disease-specific symptoms were
collected. Where missing observations were observed for
any recorded symptom, it was assumed to be asymptom-
atic. A new variable was created according to the pres-
ence/absence of these symptoms to determine whether
the patient had experienced any type of symptomatology
or not.
Complications
A list of several complications (yes/no answers) were
collected throughout the course of the follow-up period
(intra-surgical, during the hospital admission post-
surgical, and at 30 days and 1, 2, 3 and 5 years after the
intervention). If missing data were observed for each
item in the aforementioned list, no complication was
considered to have occurred. Subsequently, at each
measurement point, an overall dichotomous variable was
defined to classify patients as with and without compli-
cations. Complications were also classified into different
types, infectious, hematological, surgical or medical.
Surgical severity
We redefined the surgical severity variable into three
categories (moderate, major or complex major) depend-
ing on the type of procedure used to excise the tumor or
to palliate symptoms.
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endoscopic microsurgery (TEM) or discharge colostomy;
the major severity category to surgical techniques such
as right/left hemicolectomy, any colectomy, total procto-
colectomy, sigmoidectomy or transanal resection; and
the complex major severity category corresponded to
anterior resections or abdominoperineal amputation.
Any intervention that involved a surgical colorectal tech-
nique, in addition to another procedure that affected any
other organ, was considered a complex major surgical
intervention.
We did not consider any colorectal cancer surgeries as
belonging to the minor severity category.
pTNM staging
TNM classification was assessed according to the
American Joint Committee on Cancer (AJCC), 7th
Edition 2010 [14], and focused on the pre-intervention/
clinical (cTNM) and the histopathological report
(pTNM). For the final stage grouping, pTNM was con-
sidered. When only partial pTNM was available, a com-
bination of cTNM and pTNM data were considered: (a)
where the pM component was not recorded, pM was re-
placed by the corresponding cM stage or, when the latter
was missing, pM was assumed to be pM0; (b) in subjects
whose pN component was unobserved, the pTNM was
classified as at least stage III if there was evidence that
lymph nodes were infiltrated. Otherwise, pTNM was
specified as stage II; and (c) tumors without pT value de-
scribed pN0-pNx and pM0-pMx parameter values,
where pTNM was therefore deemed to be stage II.
When pTNM was fully unobserved, it was replaced by
the analogous cTNM data. If the latter information was
also missing, it was recorded as a missing value.
C. Statistical Analysis
In relation to the different study objectives, explora-
tory analysis of the population sample will be performed
using mean and standard deviations for continuous vari-
ables (or median and interquartilic ranges, when the
observed variables do not follow the normality distribu-
tion) and frequencies and percentages for qualitative
variables.
Predictive models will be developed to address objec-
tives 1 and 2. The overall sample will be randomly divided
into derivation and validation sets. On the one hand, for
binary outcomes (such as death, tumor recurrence, major
complications, or readmission), multivariate hierarchical
logistic models will be used. Goodness-of-fit of models
will be assessed by means of the Hosmer–Lemeshow test
(p-values > 0.05 indicate good model calibration) and the
area under the Receiver Operating Curve (ROC), AUC,
will be used to evaluate the discrimination ability of thefinal performance models. An AUC value > 0.80 will indi-
cate that the model discriminates well. Furthermore,
multivariate Cox regression models will be used to answer
to those objectives. On the other hand, in cases of con-
tinuous outcomes (variables related to deterioration of
quality of life) as with objective 3, the use of multivariate
hierarchical linear mixed models is proposed. The intra-
class correlation coefficient (ICC) will be calculated to as-
sess the correlation among observations within a cluster
by dividing the patient variance by the total sample vari-
ance. A small coefficient would indicate that patients and
participant centers are independent.
For study endpoints related to health services re-
search, the following statistical approaches will be used:
for two-level outcomes, the Student’s t-distribution or
the non-parametric Wilcoxon test (for non-normal dis-
tributions) will be applied. Where there are three or
more categories in the outcome, ANOVA analysis or a
Kruskal–Wallis approach (for non-normal distribution)
are the proposed tests. Otherwise, for categorical vari-
ables, the Chi-square test (or Fisher’s Exact method,
where required) will be used. Multivariate models will
be used as needed for appropriate adjustments. For
some analyses, subgroups based on tumor location
(colon or rectum) will be identified.
An analysis of comparative costs between two alterna-
tive surgical approaches (open and laparoscopic surgery)
will be performed. For this purpose, generalized linear
models (GLM) will be employed using the patient level
cost as the dependent variable and taking clinical covari-
ates into account (age, sex, stage, among others). The
statistical model will determine which covariates are as-
sociated with higher costs, as well as any significant dif-
ferences in cost between the two alternatives. Analysis
will be conducted at 2 and 5 years of follow up.
Finally, results related to treatment will be a valuable
source of information for inclusion in a discrete-event
simulation model reproducing a colorectal cancer-
screening program. Clinical and quality of life data for
treatment of colorectal cancer detected by screening or
clinical approaches will be useful to assess not only the
impact of screening, but also to compare different treat-
ment strategies through a cost-effectiveness or budget
impact analysis.
Quality assurance
Reviewers were instructed in the identification of pertin-
ent data and a specific manual was developed to aid in
data collection. All data is maintained in an “ad hoc”
database. Personal patient data that may allow identifica-
tion of patients will be maintained separately from the
main database, where all clinical and PRO data are in-
cluded. To access the database, specific usernames and
passwords are required. A log has been developed to
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places in the servers of participating hospitals. Each hos-
pital has a designated person in charge of the supervi-
sion of the data collection who serves as a referral
contact for the reviewers. A project manager coordi-
nated the study in the initial 2 years, with study coordin-
ation checks performed every 6 months to evaluate the
quality and completeness of the data and request add-
itional information and corrections if needed. Twice
yearly, the study investigators meet to review the status
of data collection and any issues that arise.
Duration of the project
The entire project is planned to last for more than
7 years (2 years for recruitment and 5 for follow-up until
the end of 2017), until the data from the last patient has
been collected and entered into the database. Following
this, a 6-month period of error correction and final data-
base preparation is anticipated. Manuscript writing may
commence at intervals of 1, 2, 3 and 5 years of follow-
up, once errors have been corrected and agreed on by
the coordination team.
Project management
Seven study leaders are responsible for each goal and in
different geographical areas, along with one coordinator.
Dr M. Bare was tasked with the development of predic-
tion models to determine risk factors of adverse events
in the short-term. Dr J.M. Quintana is responsible for
objectives 2 (to determine risk factors of death, tumor
recurrence, major complications, readmission or deteri-
oration of quality of life in the mid-term) and 3 (evalu-
ation of patient reported outcomes from before the
intervention to the end of the follow-up period). He is
also the coordinator of the entire study. Dr M. Redondo
is responsible for objective 4 (to study the role of bio-
logical markers in the prediction of similar adverse re-
sults). The goals related to health services research are
assigned to the following: C. Sarasqueta (equity), E.
Briones (quality of care and appropriateness), A. Escobar
(evaluation of psychosocial support interventions) and
N. Fernandez-de-Larrea (cost of various surgical ap-
proaches). Dr M. Redondo and Urko Aguirre, acting as
coordinator, are responsible for the follow-up period to
3 and 5 years. The leaders of each study goal, in con-
junction with the coordinator, comprise the coordination
committee responsible for all decisions.
Ethics
All patients were informed of the objectives of the study
and invited to voluntarily participate at the first contact
and at the 3-year follow-up visit. Patients who agreed to
participate provided written consent. Two types of in-
formed consent forms were created, one for the entiresample and one for the subsampling cohort, where bio-
logical data was requested. All information was kept
confidential. The Institutional Review Boards of the par-
ticipating hospitals approved this study.
Discussion
As illustrated in Fig. 2, by the time of manuscript prep-
aration, 2749 patients had been recruited according to
the study protocol described previously, 1980 of which
had been diagnosed with colon cancer and 769 with rec-
tal cancer. This population represents a relatively large
cohort of colorectal cancer patients for prospective fol-
low up. Description of the basic characteristics of the
sample, stratified by colon or rectal cancer diagnosis, is
displayed in Table 2.
Anticipated issues
The main limitations of this type of study design are
those related to missing patients as a result of an exten-
sive follow-up period (5 years, in this instance) and, at
the same time, missing data related to some variables,
especially those related to patient questionnaires. To
minimize these risks, all patients are informed of the ob-
jectives of the study prior to enrollment and again dur-
ing the follow-up visits. Furthermore, to reduce missing
data from questionnaires, up to three letters are sent to
patients and conversion to phone visits is available upon
request. Given the lengthy follow up period, regular pa-
tient contact are established. Furthermore, the contact
physicians at each hospital remind patients of their par-
ticipation in the study where possible.
An additional issue is the reliability of data gathering
by reviewers. To standardize the collection of data and
avoid errors, all reviewers are adequately trained and
have received specific instructions on how to collect data
for each variable.
Expected outcomes of the study
The identification of potential risk factors for adverse
events (death, major complications, relapse, reoperations
or readmission) in the short- and medium-term has un-
deniable practical value from a clinical perspective.
These data will assist clinicians to identify and predict
possible unwanted outcomes, establish preventive mea-
sures, if feasible, to correct these outcomes should they
occur, and provide patients with a medium-term prog-
nosis. In addition, the development of simple clinical
prediction rules that are easy-to-implement in daily
practice on desktop computers, tablet, mobile phones,
and other devices may facilitate clinicians in making de-
cisions to prevent such occurrences.
The large cohort of patients who have undergone sur-
gery for colon or rectal cancer followed by 5 years of
Quintana et al. BMC Cancer  (2016) 16:435 Page 10 of 12post-surgical follow up may provide useful information
to help address other health services research questions.
Dissemination of results and publication policy
For the purpose of this study, a research group called
REDISSEC CARESS-CCR (Results and Health Services
Research in Colorectal Cancer)- has been established,
and reflects the primary research participants of each
center. For publication policy purposes, an author has to
fulfill the necessary requirements by contributing to
each of three activities: 1) conception/design and/or ana-
lysis/interpretation, 2) writing, and 3) approval of final
version, and take public responsibility for the content of
the paper. All co-authors have to review and agree with
the contents of the manuscript as submitted. Due to the
study objectives, the entire study and manuscripts will
follow the STROBE guidelines for conducting and dis-
seminate observational studies and the TRIPOD state-
ment for reporting of a multivariable prediction model
for individual prognosis or diagnosis [33, 34].
The main study results will be disseminated in the
media, to clinicians, managers and policy makers in the
proper format.
Additional file
Additional file 1: Table S1. Grouping of complications. Table S2.
Chemotherapy information at the beginning of the study. (DOCX 17 kb)
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